profit from every $100 of sales.
$0$100
Zhengye Biotechnology
$1.52-1.30% today
-28.3% in 1 year
1-year low $0.651-year high $8.01
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Zhengye Biotechnology sold, what it kept, and what it did with the cash.
Sales went from CN¥260 million in 2022 to CN¥116 million in 2025, with -CN¥69.8 million of profit last year.
SalesProfit
Zhengye Biotechnology vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Zhengye Biotechnology | No profit yet | ||
 Merck KGaA | 25.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Zhengye Biotechnology's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 260 | 212 | 186 | 116 | |
| 148 | 118 | 91 | 24 | |
| 66 | 48 | 17 | -68 | |
| 86 | 72 | 43 | -43 | |
| 47 | 31 | 11 | -70 | |
| 0.99 | 0.67 | 0.24 | – | |
| 56.8% | 55.5% | 49.0% | 20.5% | |
| 25.4% | 22.5% | 9.2% | -58.7% | |
| 18.0% | 14.9% | 6.1% | -60.0% |
Balance sheet
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 520 | 500 | 493 | 436 |
| Cash | 10 | 15 | 19 | 50 |
| Total debt | 65 | 90 | 86 | 75 |
| Total liabilities | 163 | 161 | 141 | 130 |
| 296 | 273 | 284 | 250 | |
| 47 | 47 | 47 | – | |
| 14.6% | 10.5% | 3.9% | -16.6% | |
| 15.8% | 11.5% | 4.0% | -27.9% |
Cash flow
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 17 | 48 | 41 | 13 | |
| 27 | 12 | 28 | 13 | |
| -10 | 37 | 13 | 1 | |
| Dividends paid | 21 | 39 | 16 | 0 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- 0.0×
- 4.1×
- 683.4×
- –
- 0.1%
- -14.5%
- 0.0%
Profitability
- 20.5%
- -58.7%
- -60.0%
- -36.5%
- -17.9%
- 3.3%
- -26.1%
- -16.0%
- -21.6%
- 15.5%
Growth
- −23.5%
- –
- −94.7%
- –
- –
Financial health
- –
- 0.30
- 17.2%
- -20.1×
- 1.14
- 0.82
- 0.27
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 958
Bottom 6%of 888
Bottom 4%of 889
Bottom 41%of 987
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
12No pass
Benjamin Graham
56No pass
Philip Fisher
19No pass
Peter Lynch
26No pass
Joel Greenblatt
0No pass
Charlie Munger
13No pass
Terry Smith
6No pass
Questions about Zhengye Biotechnology
Is Zhengye Biotechnology a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Zhengye Biotechnology AI analysis
What does Zhengye Biotechnology do?
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. It is in Drug Manufacturers - Specialty & Generic.
Does Zhengye Biotechnology pay a dividend?
No. Zhengye Biotechnology does not pay a dividend at the moment.
Is Zhengye Biotechnology stock halal?
Yes. Zhengye Biotechnology passes our halal screen: its business is permitted and its debt is 16% of its market value, under the 30% limit. How we check
How has Zhengye Biotechnology stock done over the past year?
Down 28.3% over the past twelve months, to $1.52. It traded between $0.65 and $8.01 and is 81.0% below its high.
Who are Zhengye Biotechnology's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Zhengye Biotechnology's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.